Patents Examined by Benjamin P. Blumel
  • Patent number: 11510976
    Abstract: An H7 avian influenza vaccine strain which differentiates infected from vaccinated animals, a preparation method therefor, and an application. The highly pathogenic H7 avian influenza not only brings about huge economic losses to the livestock industry, but also seriously threatens public health safety. Conventional H7 avian influenza whole virus inactivated vaccines do have advantages such as being reliable in terms of effect, low in terms of cost and wide in terms of application range, but cannot serologically differentiate infected from vaccinated animals. The present invention uses NA of influenza B as a label to establish a method for constructing an H7 avian influenza vaccine strain which differentiates infection from vaccination, and may be used for the prevention, control and decontamination of the H7 avian influenza.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 29, 2022
    Assignee: Zhejiang Difference Biological Technology Co., Ltd
    Inventor: Jiasheng Song
  • Patent number: 11505786
    Abstract: Provided is an application of a label gene sequence in the preparation of an H9 avian influenza vaccine strain which differentiates influenza A virus infection from vaccination, the label gene sequence containing a DNA sequence for coding an influenza B virus NA protein extracellular region amino acid sequence. Also provided are an H9 avian influenza vaccine strain which differentiates influenza A virus infection from vaccination, a preparation method therefor, and an application.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 22, 2022
    Inventor: Jiasheng Song
  • Patent number: 11505597
    Abstract: The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: November 22, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Xianchun Tang
  • Patent number: 11491218
    Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: November 8, 2022
    Assignee: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA
    Inventors: Julio César Aguilar Rubido, Yadira Lobaina Mato, Enrique Iglesias Perez, Eduardo Pentón Arias, Gerardo Enrique Guillén Nieto, Jorge Agustín Aguiar Santiago, Sonia Gonzalez Blanco, Jorge Valdes Hernandez, Mariela Vazquez Castillo
  • Patent number: 11484589
    Abstract: Provided is a swine fever antigen fused with a porcine Fc fragment, and more particularly, to a vaccine composition having an autoimmune-enhancing effect by binding the Fc fragment to a swine fever antigen, and a preparation method thereof.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: November 1, 2022
    Assignees: BIOAPPLICATIONS INC., REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY)
    Inventors: Yongjik Lee, Dong-Jun An, Se Eun Choe, Jae-Young Song, In-Soo Cho
  • Patent number: 11480391
    Abstract: Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 25, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Patent number: 11479582
    Abstract: Anti-SARS-CoV-2 fusion peptides are provided. The anti-SARS-CoV-2 fusion peptides include peptide sequences corresponding to the sequence of the SARS-CoV-2 fusion complex heptad repeat domain HR2 and having at least one artificial mutation. The anti-SARS-CoV-2 fusion peptides may be 39-mers, such as peptides #121 (SEQ ID NO: 2) and #125 (SEQ ID NO: 5). These peptides may competitively bind to SARS-CoV-2 and prevent either membrane mediated SARS-CoV-2 fusion, endocytosis-mediated viral entry, or both. The anti-SARS-CoV-2 fusion peptides may be administered to a subject in need thereof to inhibit or prevent SARS-CoV-2 cellular entry.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: October 25, 2022
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mahmoud Kandeel Elsayed, Mizuki Yamamoto, Jin Gohda, Jun-Ichiro Inoue, Yasushi Kawaguchi, Hyung-Joo Kwon, Abdulla Al-Taher
  • Patent number: 11473154
    Abstract: The present invention relates to methods of identifying viral hemorrhagic septicemia virus (VHSV) and detecting mutations in VHSV by use of a PNA probe that binds specifically to VHSV non-virion gene and by analysis of the melting pattern of the PNA probe. According to the present invention, a mutation in a virus that causes infectious disease in aquatic organisms can be detected in a simple, rapid and accurate manner, infection of fish with the virus can be detected, and a mutation in the NV gene can be detected.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: October 18, 2022
    Assignee: NATIONAL FISHERY PRODUCTS QUALITY MANAGEMENT SERVICE
    Inventors: Jee Youn Hwang, Miyoung Cho, Mun Gyeong Kwon, Bo-Young Jee, Jung Soo Seo, Seong Don Hwang, Myoung Ae Park, Maeng Hyun Son
  • Patent number: 11464851
    Abstract: A pharmaceutical product for use as a vaccine against a viral disease in a human or animal subject, comprising three compositions comprising activated, autologous dendritic cells, loaded with three different SARS-CoV2 peptides, to be administered in three separate doses sequentially to the human or animal subject.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: October 11, 2022
    Assignee: R.G.C.C. Holdings AG
    Inventor: Ioannis Papasotiriou
  • Patent number: 11453714
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing influenza virus activity, thus providing a means of treating or preventing influenza infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the influenza HA for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: September 27, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lisa A. Purcell, Jonathan Viau, William Olson
  • Patent number: 11445742
    Abstract: A method of making coated avian egg yolk cores includes providing dried avian egg yolk cores having a diameter of 100 to 1500 micrometers, applying avian egg albumen to the dried avian egg yolk cores to provide the coated avian egg yolk cores, and optionally drying the coated avian egg yolk cores, wherein the ratio of dry avian egg albumen to dried avian egg yolk in the coated avian egg yolk cores is 1:10 to 10:1. Also included are the coated avian egg yolk cores, food and feed additives containing the coated avian egg yolk cores and food and feed compositions containing the coated avian egg yolk cores.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: September 20, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jordan Marshall Sand, Mark Eric Cook
  • Patent number: 11439702
    Abstract: The present specification discloses recombinant nucleic acid constructs encoding an immunogenic multiepitope polypeptide comprising two or more polypeptides, recombinant nucleic acid constructs encoding at least two epitopes from two or more internal proteins of influenza virus, compositions comprising such recombinant nucleic acid constructs and methods of eliciting a T cell immune response against an influenza virus in a vertebrate using such recombinant nucleic acid constructs and compositions.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: September 13, 2022
    Assignee: PepTcell Limited
    Inventors: Gregory A. Stoloff, Wilson Romero Caparros-Wanderley
  • Patent number: 11439701
    Abstract: The present invention relates to vaccines for treating bovine respiratory disease. Such vaccines contain a combination of bovine influenza D virus and Mannheimia haemolytica antigens. An upper respiratory infection with an IDV leads to an increased potential for M. haemolytica pathology in the lungs. The vaccines may contain further antigens from other bovine respiratory pathogens.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: September 13, 2022
    Assignee: Elanco US Inc
    Inventors: Lucas Huntimer, Thomas Halbur
  • Patent number: 11426457
    Abstract: The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell C1 epitopes, wherein the peptide is attached to a nanoparticle.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 30, 2022
    Assignee: EMERGEX VACCINES HOLDING LIMITED
    Inventor: Ramila Philip
  • Patent number: 11426461
    Abstract: The invention relates to a method for preventing dengue disease and hepatitis A in a subject or subject population by simultaneously administering a unit dose of a dengue vaccine composition and a hepatitis A vaccine on the same day. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: August 30, 2022
    Assignee: Takeda Vaccines, Inc.
    Inventor: Derek Wallace
  • Patent number: 11426459
    Abstract: The disclosure relates to a mutant of hemagglutinin protein of H3N2 subtype influenza virus and use thereof. In addition, the disclosure also relates to a pharmaceutical composition (e.g., a vaccine) comprising the mutant, a method for preparing the mutant, and a method of using the mutant for prevention and/or treatment of an infection of influenza virus and/or a disease (e.g., an influenza) caused by the infection.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 30, 2022
    Assignee: Xiamen University
    Inventors: Yixin Chen, Chenguang Shen, Junyu Chen, Mengya Zhang, Limin Zhang, Ningshao Xia
  • Patent number: 11413341
    Abstract: The compositions and methods are described for generating an immune response to an antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens as a fusion product with a viral glycoprotein and matrix protein for generating a protective immune response to a subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat diseases.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: August 16, 2022
    Assignee: Geovax, Inc.
    Inventors: Harriet Robinson, Arban Domi, Michael Hellerstein, Farshad Guirakhoo, Nathanael Paul McCurley
  • Patent number: 11389525
    Abstract: The present invention relates to a nucleic acid vaccine. Specifically, the use of a single nucleic acid sequence comprising combinations of influenza genes coding for selected hemagglutinin (HA), neuraminidase (NA), matrix protein 1 (M1), matrix protein 2 (M2) and nucleoprotein (NP) interspaced with selected linkers comprising cleavage sites to produce individual proteins, together forming one polyvalent influenza vaccine for use in medicine for humans and animals.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: July 19, 2022
    Inventors: Charlotta Polacek, Anders Fomsgaard
  • Patent number: 11382886
    Abstract: Methods for treating cancer are disclosed which comprise administering to a subject T cells which have been pretreated ex vivo or in vitro with a fatty acid catabolism promoter to condition the T cell to use fatty acids rather than glucose for energy production. Still other methods comprise co-administering to a subject having a cancer characterized by a solid tumor (a) an immunotherapeutic composition targeting an antigen or ligand on the tumor cell; and (b) a compound or reagent that promotes the use of fatty acid catabolism by tumor antigen-specific T cells in the tumor microenvironment and/or T cells pretreated ex vivo with the fatty acid catabolism promoter to condition the T cell to use fatty acids rather than glucose for energy production for adoptive cell transfer. Both methods may also employ co-administration of a checkpoint inhibitor.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: July 12, 2022
    Inventors: Hildegund C. J. Ertl, Ying Zhang
  • Patent number: 11384339
    Abstract: The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: July 12, 2022
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Yoshihiro Kawaoka, Gabriele Neumann, Makoto Ozawa